From managing to mastering GtN: A US pharma strategy for ROI optimization

So much value is lost in the space between what pharma companies expect to earn and what they actually realize. In the US, this gross-to-net drag now tops $356 billion, yet many still treat it as accounting, not strategy. It’s time to change that. GtN mastery means making it a core pharma strategy for ROI optimization – spending smarter, not more.

For years, gross-to-net (GtN) has been a back-office calculation in US pharma and biotech pricing strategy. Finance tracks the waterfall, while commercial teams account for a wide range of concessions. But the list keeps growing: rebates and discounts, patient assistance programs (PAPs), wholesaler and distribution fees, and other government and channel discounts. The collective spend creates a GtN drag estimated at more than $356 billion annually, with…